Cingulate Inc. 10-K Summary: Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Cingulate Inc. is a clinical-stage biopharmaceutical company developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform. The company focuses on treating Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. This report covers the fiscal year ended December 31, 2025. The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(22.45) million | $(16.56) million |
| Operating Expenses | $20.0 million | $15.6 million |
| Cash and Cash Equivalents (Year-End) | $10.95 million | $12.21 million |
| Accumulated Deficit | $(132.4) million | $(109.9) million |
| Debt Obligations (Notes Payable) | $7.45 million (Total) | $4.96 million (Total) |
Note: The filing text does not provide specific gross margin or operating margin data as the company has no revenue.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 35.6% to $22.45 million in 2025 from $16.56 million in 2024. This was driven by a 63.9% increase in General and Administrative (G&A) expenses to $10.16 million, primarily due to pre-commercialization costs and personnel expenses.
- Research & Development (R&D): R&D expenses increased slightly by 3.5% to $9.77 million. This was due to increased regulatory costs and manufacturing costs for pre-process validation batches, partially offset by a decrease in clinical operations costs.
- Debt Structure: The company issued a new $6.57 million unsecured promissory note in November 2025 (2025 Note) and partially extinguished a prior $5.48 million note (2024 Note) through debt-for-equity exchanges.
- Capital Raises: The company raised approximately $10.15 million in net proceeds from equity issuances in 2025 via At-The-Market (ATM) offerings and Lincoln Park Purchase Agreements.
Guidance, Outlook, and Risks
- Regulatory Milestone: The company submitted a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate for ADHD), on July 31, 2025. The FDA accepted the NDA for review and assigned a PDUFA target action date of May 31, 2026.
- Manufacturing Inspection: In February 2026, the FDA conducted a pre-approval inspection of the CDMO facility. The facility received a Form 483 with three observations (two facility-related, one product-specific). The company is working on responses.
- Liquidity and Going Concern: The company reported an accumulated deficit of $132.4 million and incurred recurring losses. The independent auditor has issued a "Going Concern" opinion, stating there is substantial doubt about the company's ability to continue operations for one year without additional funding. Management believes current cash plus recent private placement proceeds will satisfy needs through late Q4 2026.
- Commercialization Partners: Pending approval, the company plans to commercialize CTx-1301 via partnerships with Indegene (marketing, market access) and IQVIA (field sales).
- Debt Covenants: The 2025 Note contains restrictive covenants, including limitations on issuing securities and potential interest rate increases upon default events.
Key Facts for Investor Verification
- CTx-1301 Approval Probability: Verify the status of the FDA Form 483 responses and whether they impact the May 31, 2026 PDUFA date.
- Cash Runway: Confirm the exact cash burn rate and the sufficiency of the $12.0 million private placement (closed Feb 2026) to fund operations through the FDA decision and potential commercialization.
- Debt Obligations: Review the terms of the 2025 Note with Avondale Capital, specifically the redemption schedule starting May 2026 and the potential for interest rate hikes upon default.
- Commercialization Readiness: Assess the readiness of third-party partners (Indegene, IQVIA) and the CDMO (Bend Bioscience) to scale manufacturing and sales immediately upon approval.
- Secondary Pipeline: Verify the capital requirements and timelines for advancing CTx-1302 (dextroamphetamine) and CTx-2103 (buspirone), which are not yet in pivotal trials.